<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of inflammatory myopathies</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of inflammatory myopathies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of inflammatory myopathies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Greenberg, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ira N Targoff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H18308386"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The inflammatory myopathies are a group of disorders sharing the common feature of immune-mediated muscle injury. Clinical and histopathologic distinctions between these conditions suggest that different pathogenic processes underlie each of the inflammatory myopathies. The most common of these disorders include:</p><p class="bulletIndent1"><span class="glyph">●</span>Dermatomyositis (DM)</p><p class="bulletIndent1"><span class="glyph">●</span>Polymyositis (PM)</p><p class="bulletIndent1"><span class="glyph">●</span>Antisynthetase syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Immune-mediated necrotizing myopathy (IMNM)</p><p class="bulletIndent1"><span class="glyph">●</span>Inclusion body myositis (IBM)</p><p class="bulletIndent1"><span class="glyph">●</span>Nonspecific myositis</p><p></p><p>Other subtypes of inflammatory myopathy include eosinophilic myositis and granulomatous myositis. Many patients with inflammatory myopathies cannot be assigned to any category and may be classified as having nonspecific myositis [<a href="#rid1">1,2</a>]. The precise mechanisms leading to tissue injury in the inflammatory myopathies are incompletely defined in most cases.</p><p>The pathogenesis of the inflammatory myopathies, including DM, IBM, IMNM, antisynthetase syndrome, and PM, is reviewed here. The clinical manifestations, diagnosis, and treatment of the inflammatory myopathies, the pathogenesis of juvenile DM and PM, and overlap syndromes associated with systemic rheumatic diseases are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/127066.html" rel="external">"Overview of and approach to the idiopathic inflammatory myopathies"</a> and  <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5160.html" rel="external">"Initial treatment of dermatomyositis and polymyositis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5133.html" rel="external">"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5162.html" rel="external">"Malignancy in dermatomyositis and polymyositis"</a> and  <a class="medical medical_review" href="/z/d/html/6409.html" rel="external">"Juvenile dermatomyositis and other idiopathic inflammatory myopathies: Diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6419.html" rel="external">"Juvenile dermatomyositis and other idiopathic inflammatory myopathies: Epidemiology, pathogenesis, and clinical manifestations"</a> and  <a class="medical medical_review" href="/z/d/html/6418.html" rel="external">"Juvenile dermatomyositis and polymyositis: Treatment, complications, and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/5163.html" rel="external">"Clinical manifestations and diagnosis of inclusion body myositis"</a> and  <a class="medical medical_review" href="/z/d/html/5164.html" rel="external">"Management of inclusion body myositis"</a> and  <a class="medical medical_review" href="/z/d/html/1831.html" rel="external">"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes"</a>.)</p><p class="headingAnchor" id="H3852897822"><span class="h1">PATHOGENESIS OF MAJOR SUBSETS OF MYOPATHIES</span><span class="headingEndMark"> — </span>The development of genomic technologies spawned by the Human Genome Project have opened a new era in our understanding of the pathogenesis of inflammatory myopathies. These technologies include transcriptomic profiling by microarray and ribonucleic acid (RNA) sequencing (RNA-seq), protein profiling by proteomics and refinements in flow cytometry such as cytometry by time of flight (CyTOF), and hybrid RNA/protein methods such as cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq). These technologies have enabled deep, unbiased discovery of pathophysiologic mechanisms in inflammatory myopathy muscle tissue. The linking of these mechanisms to clinical features, blood biomarkers, and conventional microscopy is radically changing previous views of the pathogenesis of inflammatory myopathies. The pathogenetic mechanisms are discussed further below.</p><p class="headingAnchor" id="H18308393"><span class="h2">Dermatomyositis</span><span class="headingEndMark"> — </span>The precise pathogenic mechanisms responsible for dermatomyositis (DM) are unknown. The application of genomic technologies to DM skin and muscle samples has suggested that DM pathology results from exposure to a type 1 interferon (IFN) causing capillary, myofiber, and keratinocyte injury [<a href="#rid3">3-7</a>].</p><p>By contrast, an earlier model of DM myofiber injury resulting from an antibody- and complement-mediated microangiopathy had predominated, largely on the basis of microscopic observations of muscle biopsies [<a href="#rid8">8,9</a>]. The microscopic pathology of DM is unique among all muscle diseases, consisting of perifascicular atrophy, capillary abnormalities and loss, and perimysial abnormalities. Perifascicular myofibers, located at the boundaries between fascicles and perimysial connective tissue, are preferentially affected relative to central fascicular myofibers. These fibers are atrophic and, by microscopic histochemical techniques, express molecules typically associated with "regeneration," such as neonatal myosin (MHY8), vimentin, and natural cell adhesion molecule (NCAM), though it is unlikely these myofibers are regenerating.</p><p class="headingAnchor" id="H206354349"><span class="h3">Type 1 interferon</span><span class="headingEndMark"> — </span>There is substantial evidence that the induction of type 1 IFN-inducible gene products, both transcripts and proteins, driven by IFN-beta (IFNB), is highly and specifically associated with DM [<a href="#rid3">3,4,6</a>]. The human type 1 IFNs consist of IFN-alpha (IFNA), IFNB, IFN-kappa (IFNK), and several other subtypes, but do not include IFN-gamma (IFNG).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1 IFN-inducible transcripts in muscle</strong> – Large-scale profiling, using microarrays, of messenger RNA (mRNA) transcripts abundant in inflammatory myopathy muscle has shown very high levels of both immunoglobulin transcripts and many transcripts that are known to be induced by type 1 IFN, IFNA, and IFNB [<a href="#rid7">7,10-12</a>]. Type 1 IFN-inducible transcripts are the single most upregulated pathway present in DM muscle, with approximately 90 percent of the highest differentially upregulated transcripts belonging within this class. The degree of upregulation of most of these transcripts is unique to DM among inflammatory myopathies [<a href="#rid6">6</a>]. For example, the transcript for IFN-stimulated gene 15 (ISG15) was 570-fold higher, and myxovirus resistance protein A (MxA) was 280-fold higher, in DM than in normal muscle, compared with approximately 5-fold higher levels compared with normal for each in inclusion body myositis (IBM) [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1 IFN-inducible proteins in muscle</strong> – Among patients with DM, the type 1 IFN-inducible protein, MxA, has been observed to be densely expressed on perifascicular myofibers and sometimes on all myofibers  (<a class="graphic graphic_picture graphicRef127875" href="/z/d/graphic/127875.html" rel="external">picture 1</a>) [<a href="#rid7">7</a>]. MxA expression in myofibers is specific to DM, and MxA is also overexpressed in the epidermis [<a href="#rid14">14</a>]. The most sensitive and specific diagnostic histologic marker of DM is the expression of MxA, a type 1 IFN-inducible protein, by perifascicular myofibers [<a href="#rid7">7,15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1 IFNs in muscle and blood</strong> – The high specificity of the presence of type 1 IFN-inducible transcripts and proteins in DM muscle suggests that DM muscle is exposed to high concentrations of a type 1 IFN. Which specific type 1 IFN(s) drive this induction in DM muscle is unknown and will likely only be determined by clinical trials of selective type 1 IFN neutralization. The available biomarker evidence strongly suggests that IFNB is the driving cytokine. Blood measurements of type 1 IFN protein serum levels have shown association of IFNB but not IFNA with DM type 1 IFN signature [<a href="#rid17">17</a>] and disease activity [<a href="#rid18">18</a>]. Most remarkably, RNA-seq muscle transcript profiling has shown remarkable specificity for IFNB muscle transcript in DM, among all type 1 IFN subtypes and all categories of inflammatory myopathy  (<a class="graphic graphic_figure graphicRef127870" href="/z/d/graphic/127870.html" rel="external">figure 1</a>). The cellular source of IFNB and potentially other type 1 IFNs in DM muscle is unknown, but is likely fibroblasts in the muscle perimysial region or skin dermis, or myofibers and keratinocytes themselves. An alternative possibility is from locally infiltrating plasmacytoid dendritic cells (pDCs) [<a href="#rid7">7,19</a>].</p><p></p><p>Relying upon these and other observations, a model of the pathogenesis of DM resulting from the induction of type 1 IFN-inducible gene products after exposure to type 1 IFNs can be constructed [<a href="#rid5">5</a>]. Production of a type 1 IFN, particularly IFNB by fibroblasts, myocytes, and keratinocytes, leads to sustained accumulation of intracellular (within myofibers and keratinocytes) type 1 IFN-inducible transcripts and proteins. These injure myofibers and keratinocytes through mechanisms unknown.</p><p class="headingAnchor" id="H18308436"><span class="h3">Autoantibodies</span><span class="headingEndMark"> — </span>Autoantibodies with affinities for various antigens, such as the aminoacyl transfer RNA (tRNA) synthetases, have been reported in DM and other inflammatory myopathies [<a href="#rid20">20-22</a>]. The pathogenic role of any of these autoantibodies is uncertain and continues to be explored, although the detection of these autoantibodies may be useful clinically because of their association with particular clinical syndromes. (See  <a class="medical medical_review" href="/z/d/html/127066.html" rel="external">"Overview of and approach to the idiopathic inflammatory myopathies", section on 'Myositis-specific autoantibodies'</a>.)</p><p>DM has increasingly been recognized as constituting a number of subtypes defined by the presence of specific autoantibodies [<a href="#rid23">23</a>]. The earliest identified DM syndrome-associated autoantibodies were the antisynthetase syndromes, typified by anti-Jo-1, though these are associated with polymyositis (PM) as well [<a href="#rid20">20</a>]. More recent DM subtypes associated with anti-melanoma differentiation-associated protein 5 (anti-MDA5), anti-transcription intermediary factor 1-gamma (anti-TIF1-gamma), anti-nuclear matrix protein 2 (anti-NXP2), and anti-small ubiquitin-like modifier activating enzyme (anti-SAE) have been defined with specific clinical manifestations. The role of these autoantibodies in DM pathogenesis is unknown.</p><p class="headingAnchor" id="H1455213961"><span class="h2">Polymyositis</span><span class="headingEndMark"> — </span>The definition of PM has evolved since the disease was first described, resulting in challenges identifying true pathogenetic mechanisms. PM was first reported in 1886. The recognition of skin rash in some patients led to distinction of DM by 1891, but PM remained the sole diagnostic category for patients with myositis other than DM for the next 90 years. Subsequently, there has been a progressive splitting off of syndromes from PM into more specific categories, first with IBM (1978), then with immune-mediated necrotizing myopathy (IMNM; 1991), and with antisynthetase syndrome. What remains of this initially highly heterogeneous category of PM is a matter of differing opinions. Some investigators prefer the term nonspecific myositis [<a href="#rid1">1</a>] or unclassified myositis [<a href="#rid24">24</a>] over PM to reflect its continued heterogenous nature. In addition, some patients with muscular dystrophies related to dysferlin and calpain-3 mutations have been misdiagnosed with PM because of the presence of immune cells in muscle biopsies. (See  <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a> and <a class="local">'Immune-mediated necrotizing myopathy'</a> below.)</p><p>The heterogenous nature of a lumped category like PM has created particular confusion with regard to the pathogenesis of the diseases included in it. Numerous publications have viewed PM as a disease in which lymphocytes, particularly CD8+ cytotoxic T cells, invade myofibers, with similar or identical immunologic mechanisms as are seen in IBM. Unfortunately, the misdiagnosis of patients with IBM as having PM largely contributed to this view. Some investigators have reported that almost all patients with initial lymphocytic invasion of myofibers have IBM after follow-up [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H4093183744"><span class="h2">Antisynthetase syndrome</span><span class="headingEndMark"> — </span>As with IMNM, antisynthetase syndrome has historically been lumped within the category of "polymyositis" (PM), but its distinctive features warrant separate classification [<a href="#rid25">25</a>] (see  <a class="medical medical_review" href="/z/d/html/127066.html" rel="external">"Overview of and approach to the idiopathic inflammatory myopathies", section on 'Antisynthetase syndrome'</a>). This disease is characterized by multiple-organ involvement in addition to myositis (and sometimes without myositis), primarily interstitial lung disease, non-erosive arthritis, Raynaud phenomenon, and "mechanic's hands." The last feature has variably been interpreted as a feature of DM. Autoantibodies directed to eight different aminoacyl tRNA synthetases define this category, with anti-Jo-1 being the most common. Multiple immune components, including T cells, have been suggested as pathogenic factors [<a href="#rid26">26</a>] (see  <a class="medical medical_review" href="/z/d/html/127066.html" rel="external">"Overview of and approach to the idiopathic inflammatory myopathies", section on 'Myositis-specific autoantibodies'</a>). The role of autoantibodies is unclear, as mouse models of myositis induced by immunization with histidyl tRNA synthetase are not dependent on the development of antibody responses [<a href="#rid27">27</a>] and have been hypothesized to be mediated by innate immune mechanisms or by the action of histidyl tRNA synthetase as a chemokine [<a href="#rid27">27</a>]. More generally, activation of multiple components of the innate and adaptive immune system may play a role in the pathogenesis of antisynthetase syndromes [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H3949709746"><span class="h2">Immune-mediated necrotizing myopathy</span><span class="headingEndMark"> — </span>IMNM was identified as distinct from "polymyositis" (PM) in the early 1990s [<a href="#rid29">29</a>]. Three subtypes of IMNMs are recognized [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-signal recognition particle (anti-SRP) autoantibody IMNM [<a href="#rid31">31</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) autoantibody IMNM [<a href="#rid32">32</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-HMGCR/SRP-negative IMNM</p><p></p><p>Histologically, IMNM is characterized by scattered necrotic and regenerating fibers (often many more regenerating fibers than fibers undergoing necrosis) with relative absence of lymphocyte infiltration and abundance of macrophage infiltration [<a href="#rid33">33</a>]. Anti-HMGCR myopathy is strongly associated with both the class II major histocompatability complex (MHC) allele DRB1*11:01 and exposure to statin drugs, suggesting it results when genetically susceptible individuals upregulate HMGCR, particularly after statin exposure [<a href="#rid34">34</a>]. The pathophysiology of anti-SRP autoantibody IMNM is less understood. The mechanism of myofiber injury for all forms of IMNM is even less clear, speculatively related to autoantibody binding to the surface of myofibers and subsequent complement-mediated cellular injury [<a href="#rid34">34</a>]. Notably, in anti-HMGCR, anti-SRP, and in those IMNM cases with no serum antibodies, muscle biopsies reveal expression of MHC class 1 (MHC1) and membrane attack complex (MAC) deposition on the sarcolemma of non-necrotic fibers, suggesting that muscle destruction might be complement mediated. Deposition of MHC1 and MAC on sarcolemma of non-necrotic muscle fibers is not seen in toxic myopathies nor other autoimmune inflammatory myopathies. (See  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events"</a>.)</p><p class="headingAnchor" id="H2535303"><span class="h2">Other myopathies</span><span class="headingEndMark"> — </span>Other forms of myositis have been described, some of which exhibit characteristic histologic features. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced myopathy</strong> – Several drugs appear to contribute to the development of inflammatory myopathy, including statins, IFNA and IFNB, tumor necrosis factor (TNF) inhibitors, L-tryptophan, and others [<a href="#rid35">35-48</a>]. Interpreting causality is often confounded by the presence of the underlying disease for which the drugs are being used. This topic is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5166.html" rel="external">"Drug-induced myopathies"</a> and  <a class="medical medical_review" href="/z/d/html/5166.html" rel="external">"Drug-induced myopathies", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events"</a> and <a class="local">'Immune-mediated necrotizing myopathy'</a> above and  <a class="medical medical_review" href="/z/d/html/7557.html" rel="external">"Risk factors for and possible causes of systemic sclerosis (scleroderma)", section on 'L-tryptophan'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilic myositis</strong> – Eosinophilic myositis is sometimes classified as a form of PM. The only distinctive feature is the presence of eosinophils in muscle biopsy sections and, occasionally, blood eosinophilia. Chronic parasitic infection is one known cause of this syndrome. Remarkably, some patients with eosinophilic myositis have mutations in calpain-3 [<a href="#rid49">49,50</a>]. Mutations in this gene also result in an inherited muscular dystrophy syndrome (limb-girdle muscular dystrophy type 2A). The mechanisms by which calpain-3 mutations lead to recruitment of eosinophils to muscle are unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granulomatous myositis</strong> – Granulomatous myositis is a clinical syndrome of distal asymmetric weakness and the presence of granulomas in muscle biopsy sections  (<a class="graphic graphic_picture graphicRef74647" href="/z/d/graphic/74647.html" rel="external">picture 2</a>). It may occur with systemic involvement leading to a diagnosis of sarcoidosis [<a href="#rid51">51</a>] or graft-versus-host disease [<a href="#rid52">52,53</a>], or it can be idiopathic, without another associated illness [<a href="#rid51">51,54</a>]. Macrophages, lymphocytes, and plasma cells are present in the affected muscle, but the mechanisms of idiopathic granulomatous myositis are unknown [<a href="#rid54">54</a>]. Case series have suggested as many as half of patients who have granulomas on muscle biopsy actually have IBM (both clinically and by repeat biopsy) [<a href="#rid55">55,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myositis associated with graft-versus-host disease</strong> – Graft-versus-host disease may be associated with myositis, characterized pathologically as a number of syndromes including DM  (<a class="graphic graphic_picture graphicRef73055" href="/z/d/graphic/73055.html" rel="external">picture 3</a>) [<a href="#rid57">57-60</a>], PM [<a href="#rid61">61</a>], and granulomatous myositis [<a href="#rid52">52,53</a>]. The pathogenesis of these syndromes is poorly understood, but the presence of infarction in some of these clearly indicates vascular injury (see panels C and D in the picture)  (<a class="graphic graphic_picture graphicRef73055" href="/z/d/graphic/73055.html" rel="external">picture 3</a>).</p><p></p><p class="headingAnchor" id="H14593170"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The inflammatory myopathies, including dermatomyositis (DM), polymyositis (PM), antisynthetase syndrome, immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), and other myopathies and related disorders, share the common feature of immune-mediated muscle injury. Clinical and histopathologic distinctions between these conditions suggest that different pathogenic processes underlie each of the inflammatory myopathies, but the precise mechanisms leading to tissue injury in the inflammatory myopathies are incompletely defined. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The precise mechanisms responsible for DM are unknown. The marked type 1 interferon (IFN) molecular abnormalities present strongly suggest a pathogenesis including overproduction of a type 1 IFN, with the available evidence suggesting IFN-beta (IFNB) predominantly. The pathogenic role of myositis-specific autoantibodies is uncertain. (See <a class="local">'Dermatomyositis'</a> above and <a class="local">'Type 1 interferon'</a> above and <a class="local">'Autoantibodies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The heterogeneous nature of a category like PM has created particular confusion with regard to the pathogenesis of the diseases included in it. There are likely a variety of immunologic mechanisms among the distinct diseases in this category. (See <a class="local">'Polymyositis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple immune components, including T cells, have been suggested as pathogenic factors in antisynthetase syndrome. (See <a class="local">'Antisynthetase syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mechanism of myofiber injury for all forms of IMNM is unknown, speculatively related to autoantibody binding to the surface of myofibers and subsequent complement-mediated cellular injury. Histologically, IMNM is characterized by scattered necrotic and regenerating fibers with relative absence of lymphocyte infiltration and expression of major histocompatability complex class 1 (MHC1) and membrane attack complex (MAC) on sarcolemma of non-necrotic fibers. (See <a class="local">'Immune-mediated necrotizing myopathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other forms of myositis have been described, some of which exhibit characteristic histologic features, including drug-induced myopathy, eosinophilic myositis, granulomatous myositis, and myositis associated with graft-versus-host disease. (See <a class="local">'Other myopathies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14:337.</a></li><li><a class="nounderline abstract_t">van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61:316.</a></li><li><a class="nounderline abstract_t">Greenberg SA. Type 1 interferons and myositis. Arthritis Res Ther 2010; 12 Suppl 1:S4.</a></li><li><a class="nounderline abstract_t">Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 2010; 12:198.</a></li><li><a class="nounderline abstract_t">Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69:2008.</a></li><li><a class="nounderline abstract_t">Salajegheh M, Kong SW, Pinkus JL, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010; 67:53.</a></li><li><a class="nounderline abstract_t">Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57:664.</a></li><li><a class="nounderline abstract_t">Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971.</a></li><li><a class="nounderline abstract_t">Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004; 17:561.</a></li><li><a class="nounderline abstract_t">Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002; 59:1170.</a></li><li><a class="nounderline abstract_t">Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005; 128:1887.</a></li><li><a class="nounderline abstract_t">Greenberg SA. A gene expression approach to study perturbed pathways in myositis. Curr Opin Rheumatol 2007; 19:536.</a></li><li><a class="nounderline abstract_t">Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007; 56:3784.</a></li><li><a class="nounderline abstract_t">Wenzel J, Schmidt R, Proelss J, et al. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 2006; 31:576.</a></li><li><a class="nounderline abstract_t">Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology 2017; 88:493.</a></li><li><a class="nounderline abstract_t">Uruha A, Allenbach Y, Charuel JL, et al. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathol Appl Neurobiol 2019; 45:513.</a></li><li><a class="nounderline abstract_t">Liao AP, Salajegheh M, Nazareno R, et al. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 2011; 70:831.</a></li><li><a class="nounderline abstract_t">Huard C, Gullà SV, Bennett DV, et al. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis. Br J Dermatol 2017; 176:1224.</a></li><li><a class="nounderline abstract_t">López de Padilla CM, Vallejo AN, McNallan KT, et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007; 56:1658.</a></li><li><a class="nounderline abstract_t">Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007; 19:523.</a></li><li><a class="nounderline abstract_t">Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184:134.</a></li><li><a class="nounderline abstract_t">Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48:607.</a></li><li><a class="nounderline abstract_t">Wolstencroft PW, Fiorentino DF. Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies. Curr Rheumatol Rep 2018; 20:28.</a></li><li><a class="nounderline abstract_t">van de Vlekkert J, Hoogendijk JE, de Visser M. Myositis with endomysial cell invasion indicates inclusion body myositis even if other criteria are not fulfilled. Neuromuscul Disord 2015; 25:451.</a></li><li><a class="nounderline abstract_t">Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 2014; 13:367.</a></li><li><a class="nounderline abstract_t">Gayed C, Uzunhan Y, Cremer I, et al. Immunopathogenesis of the Anti-Synthetase Syndrome. Crit Rev Immunol 2018; 38:263.</a></li><li><a class="nounderline abstract_t">Soejima M, Kang EH, Gu X, et al. Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis. Arthritis Rheum 2011; 63:479.</a></li><li><a class="nounderline abstract_t">Gallay L, Gayed C, Hervier B. Antisynthetase syndrome pathogenesis: knowledge and uncertainties. Curr Opin Rheumatol 2018; 30:664.</a></li><li><a class="nounderline abstract_t">Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20:224.</a></li><li><a class="nounderline abstract_t">Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2018; 28:87.</a></li><li><a class="nounderline abstract_t">Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73:420.</a></li><li><a class="nounderline abstract_t">Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63:713.</a></li><li><a class="nounderline abstract_t">Chung T, Christopher-Stine L, Paik JJ, et al. The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve 2015; 52:189.</a></li><li><a class="nounderline abstract_t">Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-Mediated Necrotizing Myopathy. Curr Rheumatol Rep 2018; 20:21.</a></li><li><a class="nounderline abstract_t">Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185.</a></li><li><a class="nounderline abstract_t">Cirigliano G, Della Rossa A, Tavoni A, et al. Polymyositis occurring during alpha-interferon treatment for malignant melanoma: a case report and review of the literature. Rheumatol Int 1999; 19:65.</a></li><li><a class="nounderline abstract_t">Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol 2000; 17:64.</a></li><li><a class="nounderline abstract_t">John A, El Emadi S, Al Kaabi S, et al. Polymyositis during pegylated alpha-interferon ribavirin therapy for chronic hepatitis. Indian J Gastroenterol 2007; 26:147.</a></li><li><a class="nounderline abstract_t">Kälkner KM, Rönnblom L, Karlsson Parra AK, et al. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998; 91:393.</a></li><li><a class="nounderline abstract_t">Lee SW, Kim KC, Oh DH, et al. A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B. J Korean Med Sci 2002; 17:141.</a></li><li><a class="nounderline abstract_t">Matsuya M, Abe T, Tosaka M, et al. The first case of polymyositis associated with interferon therapy. Intern Med 1994; 33:806.</a></li><li><a class="nounderline abstract_t">Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67:1670.</a></li><li><a class="nounderline abstract_t">Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2006; 55:982.</a></li><li><a class="nounderline abstract_t">Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008; 59:159.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86:242.</a></li><li><a class="nounderline abstract_t">Jego G, Pascual V, Palucka AK, Banchereau J. Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun 2005; 8:124.</a></li><li><a class="nounderline abstract_t">Hollander D, Adelman LS. Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan: muscle biopsy findings in 4 patients. Neurology 1991; 41:319.</a></li><li><a class="nounderline abstract_t">Somani AK, Swick AR, Cooper KD, McCormick TS. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008; 144:1341.</a></li><li><a class="nounderline abstract_t">Amato AA. Adults with eosinophilic myositis and calpain-3 mutations. Neurology 2008; 70:730.</a></li><li><a class="nounderline abstract_t">Krahn M, Lopez de Munain A, Streichenberger N, et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 2006; 59:905.</a></li><li><a class="nounderline abstract_t">Le Roux K, Streichenberger N, Vial C, et al. Granulomatous myositis: a clinical study of thirteen cases. Muscle Nerve 2007; 35:171.</a></li><li><a class="nounderline abstract_t">Bagdasaryan R, Donahue JE. Granulomatous myositis in association with chronic graft vs. host disease. Med Health R I 2007; 90:287.</a></li><li><a class="nounderline abstract_t">Kaushik S, Flagg E, Wise CM, et al. Granulomatous myositis: a manifestation of chronic graft-versus-host disease. Skeletal Radiol 2002; 31:226.</a></li><li><a class="nounderline abstract_t">Prayson RA. Granulomatous myositis. Clinicopathologic study of 12 cases. Am J Clin Pathol 1999; 112:63.</a></li><li><a class="nounderline abstract_t">Dieudonné Y, Allenbach Y, Benveniste O, et al. Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis. Neurology 2020; 94:e910.</a></li><li><a class="nounderline abstract_t">Alhammad RM, Liewluck T. Myopathies featuring non-caseating granulomas: Sarcoidosis, inclusion body myositis and an unfolding overlap. Neuromuscul Disord 2019; 29:39.</a></li><li><a class="nounderline abstract_t">Arin MJ, Scheid C, Hübel K, et al. Chronic graft-versus-host disease with skin signs suggestive of dermatomyositis. Clin Exp Dermatol 2006; 31:141.</a></li><li><a class="nounderline abstract_t">Ollivier I, Wolkenstein P, Gherardi R, et al. Dermatomyositis-like graft-versus-host disease. Br J Dermatol 1998; 138:558.</a></li><li><a class="nounderline abstract_t">Allen JA, Greenberg SA, Amato AA. Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease. Muscle Nerve 2009; 40:643.</a></li><li><a class="nounderline abstract_t">Nozaki K, Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry 2009; 80:904.</a></li><li><a class="nounderline abstract_t">Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford) 2003; 42:34.</a></li></ol></div><div id="topicVersionRevision">Topic 14918 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15099594" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12913190" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Polymyositis: an overdiagnosed entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20392291" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Type 1 interferons and myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425524" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Dermatomyositis and type 1 interferons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17928577" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20186858" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15852401" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14511932" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Polymyositis and dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367860" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12391344" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Molecular profiles of inflammatory myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15857930" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17917532" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A gene expression approach to study perturbed pathways in myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17968926" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16716166" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28039312" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Sarcoplasmic MxA expression: A valuable marker of dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30267437" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177291" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interferonβis associated with type 1 interferon-inducible gene expression in dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27564228" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Correlation of cutaneous disease activity with type 1 interferon gene signature and interferonβin dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469160" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17917530" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20146695" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19439503" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29637414" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25817837" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Myositis with endomysial cell invasion indicates inclusion body myositis even if other criteria are not fulfilled.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24424190" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30806243" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Immunopathogenesis of the Anti-Synthetase Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21280002" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30239350" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antisynthetase syndrome pathogenesis: knowledge and uncertainties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2470663" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29221629" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12235311" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Myopathy with antibodies to the signal recognition particle: clinical and pathological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21360500" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25737145" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29582188" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Immune-Mediated Necrotizing Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19813188" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Immune-mediated necrotizing myopathy associated with statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651086" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Polymyositis occurring during alpha-interferon treatment for malignant melanoma: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10713663" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dermatomyositis after interferon alpha treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17704594" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Polymyositis during pegylated alpha-interferon ribavirin therapy for chronic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709457" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11850606" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7718967" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The first case of polymyositis associated with interferon therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18272672" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17139649" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230873" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17632266" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564719" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dendritic cells control B cell growth and differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992385" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan: muscle biopsy findings in 4 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936398" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299526" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Adults with eosinophilic myositis and calpain-3 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16607617" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : CAPN3 mutations in patients with idiopathic eosinophilic myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17068767" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Granulomatous myositis: a clinical study of thirteen cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17970330" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Granulomatous myositis in association with chronic graft vs. host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904691" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Granulomatous myositis: a manifestation of chronic graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10396287" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Granulomatous myositis. Clinicopathologic study of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31882529" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30578101" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Myopathies featuring non-caseating granulomas: Sarcoidosis, inclusion body myositis and an unfolding overlap.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16309514" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Chronic graft-versus-host disease with skin signs suggestive of dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9580831" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dermatomyositis-like graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19670319" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19240048" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509610" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Polymyositis as a manifestation of chronic graft-versus-host disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
